Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J Costa, MD PhD, Yana Lutska, PharmD, Daniela Hoehn, MDPhD, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 151.

https://doi.org/10.1182/blood-2018-151

Published: 2018

Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD

Blood (2018) 132 (Supplement 1): 152.

https://doi.org/10.1182/blood-2018-152

Published: 2018

Journal Articles

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Neil E. Kay, Wenting Wu, John C. Byrd, MD, Brian Kabat, Diane F. Jelinek, PhD, Clive S. Zent, MD, Timothy Call, Thomas Lin, MD, PhD, Tait Shanafelt

Blood (2008) 112 (11): 43.

https://doi.org/10.1182/blood.V112.11.43.43

Published: 2008

Journal Articles

17-DMAG Targets the NF-κB Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

Amy J Wagner, Erin K Hertlein, PhD, Chelsey A Raymond, Derek A West, Joseph M Flynn, DO, MPH, Thomas Lin, MD, PhD, Amy J Johnson, PhD, John C Byrd, MD

Blood (2008) 112 (11): 381.

https://doi.org/10.1182/blood.V112.11.381.381

Published: 2008

Journal Articles

High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG.

Mehdi Hamadani, MD, Patrick Elder, Farrukh Awan, David Krugh, William Blum, MD, Thomas Lin, MD, PhD, Leslie Andritsos, MD, Thomas Bechtel, Kristie Blum, MD, Rebecca Klisovic, MD, Steven M. Devine, MD

Blood (2007) 110 (11): 5080.

https://doi.org/10.1182/blood.V110.11.5080.5080

Published: 2007

Journal Articles

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Arnold S. Freedman, MD, Paul A. Hamlin, MD, Sattva Neelapu, MD, Craig Nichols, MD, Michael Robertson, MD, Gregoire Bergier, MD, Jane N. Winter, MD, Jonathan Polikoff, MD, Thomas Lin, MD, PhD, Brad Pohlman, MD, Vanessa Esquibel, Teresa Melink, NP, John Bender, PharmD

Blood (2006) 108 (11): 2756.

https://doi.org/10.1182/blood.V108.11.2756.2756

Published: 2006

Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD

Blood (2005) 106 (11): 772.

https://doi.org/10.1182/blood.V106.11.772.772

Published: 2005

NARROW

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

17-DMAG Targets the NF-κB Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG.

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

17-DMAG Targets the NF-κB Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG.

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only